08.25.22 -- How Automated, Closed Systems Can Improve Cell Manufacturing

Enriching mononuclear cells (MNCs) by removing other cell types and contaminants is a critical step in CAR-T cell therapy production. This video explains why, how, and when you should carry out platelet depletion to achieve successful T cell enrichment.

There is a growing need to close and automate manufacturing of CAR-T cell therapies. Learn how to streamline this step while keeping flexibility during process development.

A new 1.2 µm pore size filter was validated for use in the Xuri™ Cell Expansion System W25, which consists of a reusable instrument and single-use Cellbag™ bioreactors. The substantially smaller pore size of the new filter membrane decreased T cell loss, ultimately leading to higher T cell retention in the Xuri™ system Cellbag™ bioreactor.

Performing dilution, concentration, and washing steps in a closed and automated manner is important in GMP cell therapy manufacturing. Using a model T cell line, we demonstrate the impact of varying rinse volume, intermediate volume, and manual extraction parameters on overall cell recovery with a final product dose volume of 20 mL.

Many studies are evaluating natural killer (NK) cells as potential cancer treatments. However, it is challenging to obtain primary NK cells at clinically relevant scale. Here, we generated 1 × 10⁹ cells in a workflow amenable to a cGMP environment. Learn the workflow for xeno-free natural killer cell expansion from leukapheresis units. 

This application note describes the details of a robust CAR-T cell manufacturing workflow that can be adapted for cGMP compliance in commercial production of CAR-T cells.